Drug Discovery & Development
HIV nanoparticle vaccine induces strong T-cell responses in early-phase clinical trial
An HIV nanoparticle vaccine has induced strong T-cell responses in a first-in-human clinical trial, marking a step toward the development of a product that protects against the virus. Read More
New antibiotic targets deadly hospital superbug
Scientists used artificial intelligence (AI) to discover a promising antibiotic that may help doctors target Acinetobacter baumannii, a deadly, drug-resistant pathogen that often strikes vulnerable hospital patients. The study, published Thursday in the journal Nature Chemical Biology, identified the antibacterial compound abaucin in response to the urgent need for new ways to treat A. baumannii infection. Read More
Study of woman who cannot feel pain finds molecular explanation for phenomenon
Researchers have uncovered the biological effects of a mutation that causes its carrier to live virtually pain-free, heal more rapidly, and experience reduced anxiety and fear. Read More
Modified anti-nausea drug enters cells, treats pain
Altering the chemical properties of the anti-nausea drug netupitant enables it to enter interior cell compartments and provide long-lasting pain relief, according to research published Monday in the Proceedings of the National Academy of Sciences (PNAS). Read More
A new look at an old antibiotic for drug resistant bacteria
Researchers are taking a new look at an 80-year-old antibiotic. The in vitro and in vivo studies, published Tuesday in the journal PLOS Biology, may offer a new tool in the fight against difficult-to-treat and potentially lethal multidrug-resistant bacterial infections. Read More
Boundless Bio closes $100 million Series C financing to advance precision oncology therapies
Next-generation precision oncology company Boundless Bio on Tuesday announced the closing of its $100 million Series C financing, which will be used to advance the clinical development of its BBI-355 extrachromosomal DNA-directed oncology therapy. Read More
Modified bacterial peptide shows early promise against drug-resistant pathogens
Work to improve the potency and reduce the toxicity of an antimicrobial peptide has yielded a molecule that inhibited multidrug-resistant bacteria (MDR) in early-stage tests. Read More
Dualyx raises 40 million euros in Series A financing to advance autoimmune therapies
Biotech firm Dualyx announced on Monday that it has raised 40 million euros (approximately $44 million) through a Series A financing round. Read More
FDA approves first drug to treat agitation associated with dementia due to Alzheimer’s
The U.S. Food and Drug Administration (FDA) on Thursday announced the supplemental approval of Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer’s disease. Read More
Alzheimer’s drug could prevent damage to the brain
Researchers showed that tiny aggregates of amyloid beta protein, a naturally occurring substance associated with Alzheimer’s disease progression, can float freely through brain tissue fluid, reaching important brain regions and disrupting local neuron functioning. The research, published Wednesday in the journal Neuron, also indicated that a newly-approved Alzheimer’s disease treatment could neutralize these tiny aggregates, also known as protofibrils or oligomers. Read More
International Paper Physics Conference 2023 (IPPC2023)
May 31 - June 2
Guangzhou, Guangdong China
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter